Matthew Crave, LCSW | |
314 Central Ave, Albany, NY 12206-2522 | |
(518) 462-1094 | |
Not Available |
Full Name | Matthew Crave |
---|---|
Gender | Male |
Speciality | Social Worker - Clinical |
Location | 314 Central Ave, Albany, New York |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1215353347 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | 077281-1 (New York) | Primary |
Entity Name | Rehabilitation Support Services, Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1245481209 PECOS PAC ID: 0446437107 Enrollment ID: O20160127002137 |
News Archive
Researchers at 17 medical centers across the country soon will begin using the hormone progesterone to treat patients who experience traumatic brain injury (TBI). The treatment is part of a randomized, double-blind Phase III clinical trial that will enroll approximately 1,140 people over a three- to six-year period beginning in March, 2010. The trial is funded by a grant to Emory University from the National Institutes of Health.
The first two contracts for advanced development of drugs to treat gastrointestinal (GI) tract injuries associated with acute radiation syndrome were awarded today by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).
PROLOR Biotech, Inc., today announced that final data from a randomized, dose-escalating Phase I clinical study of its longer-acting version of human growth hormone (hGH-CTP) will be featured in an oral presentation by PROLOR management at the 12th Annual BIO CEO & Investor Conference to be held at the Waldorf-Astoria Hotel in New York City on February 8-9, 2010.
A new study could point the way to the development of better drugs to fight a deadly form of childhood leukemia called mixed-lineage leukemia (MLL).
› Verified 5 days ago
Entity Name | Parsons Child And Family Center |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1922171305 PECOS PAC ID: 9931403656 Enrollment ID: O20160201001282 |
News Archive
Researchers at 17 medical centers across the country soon will begin using the hormone progesterone to treat patients who experience traumatic brain injury (TBI). The treatment is part of a randomized, double-blind Phase III clinical trial that will enroll approximately 1,140 people over a three- to six-year period beginning in March, 2010. The trial is funded by a grant to Emory University from the National Institutes of Health.
The first two contracts for advanced development of drugs to treat gastrointestinal (GI) tract injuries associated with acute radiation syndrome were awarded today by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).
PROLOR Biotech, Inc., today announced that final data from a randomized, dose-escalating Phase I clinical study of its longer-acting version of human growth hormone (hGH-CTP) will be featured in an oral presentation by PROLOR management at the 12th Annual BIO CEO & Investor Conference to be held at the Waldorf-Astoria Hotel in New York City on February 8-9, 2010.
A new study could point the way to the development of better drugs to fight a deadly form of childhood leukemia called mixed-lineage leukemia (MLL).
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Matthew Crave, LCSW 7 Sonya Pl, Schenectady, NY 12309-1917 Ph: (518) 935-5964 | Matthew Crave, LCSW 314 Central Ave, Albany, NY 12206-2522 Ph: (518) 462-1094 |
News Archive
Researchers at 17 medical centers across the country soon will begin using the hormone progesterone to treat patients who experience traumatic brain injury (TBI). The treatment is part of a randomized, double-blind Phase III clinical trial that will enroll approximately 1,140 people over a three- to six-year period beginning in March, 2010. The trial is funded by a grant to Emory University from the National Institutes of Health.
The first two contracts for advanced development of drugs to treat gastrointestinal (GI) tract injuries associated with acute radiation syndrome were awarded today by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).
PROLOR Biotech, Inc., today announced that final data from a randomized, dose-escalating Phase I clinical study of its longer-acting version of human growth hormone (hGH-CTP) will be featured in an oral presentation by PROLOR management at the 12th Annual BIO CEO & Investor Conference to be held at the Waldorf-Astoria Hotel in New York City on February 8-9, 2010.
A new study could point the way to the development of better drugs to fight a deadly form of childhood leukemia called mixed-lineage leukemia (MLL).
› Verified 5 days ago
Ms. Phyllis L. Adler, LCSW-R Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 40 N Main Ave, Albany, NY 12203 Phone: 518-435-6700 | |
Nancy C Mckenna, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 747 Madison Ave Ste 2, Albany, NY 12208 Phone: 518-755-0611 Fax: 518-755-0611 | |
Elizabeth Z Herr, LMSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 877 Madison Ave, Albany, NY 12208 Phone: 518-482-8856 Fax: 518-489-5839 | |
Jean E Poppei, Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 160 N Main Ave, Albany, NY 12206 Phone: 518-437-6613 | |
Ms. Emily Lezzi, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 40 N Main Ave, Albany, NY 12203 Phone: 518-918-8712 | |
Mary M Farnell, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 170 Osborne Rd, Albany, NY 12205 Phone: 518-459-8977 | |
Mr. Daniel H Cook, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1 Pinnacle Pl, Albany, NY 12203 Phone: 518-689-0244 Fax: 518-689-0241 |